Quinazolinethiones and quinazolinediones, novel inhibitors of inosine monophosphate dehydrogenase: Synthesis and initial structure-activity relationships

Bioorganic and Medicinal Chemistry Letters

Volumn 15, Issue 3, 2005, Pages 751-754

  Buckley, George M ^a   Davies, Natasha ^a   Dyke, Hazel J ^a   Gilbert, Philip J ^a   Hannah, Duncan R ^a   Haughan, Alan F ^a   Hunt, Caroline A ^a   Pitt, William R ^a   Profit, Rachael H ^a   Ray, Nicholas C ^a   Richard, Marianna D ^a   Sharpe, Andrew ^a   Taylor, Alicia J ^a   Whitworth, Justine M ^a   Williams, Sophie C ^a  

^a UCB PHARMA   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

INOSINATE DEHYDROGENASE INHIBITOR; QUINAZOLINE DERIVATIVE; QUINAZOLINEDIONE DERIVATIVE; QUINAZOLINETHIONE DERIVATIVE; UNCLASSIFIED DRUG;

ARTICLE; DRUG SYNTHESIS; ENZYME INHIBITION; PERIPHERAL BLOOD MONONUCLEAR CELL; STRUCTURE ACTIVITY RELATION;

BLOOD CELLS; CELL PROLIFERATION; ENZYME INHIBITORS; HUMANS; IMP DEHYDROGENASE; INHIBITORY CONCENTRATION 50; KETONES; MONOCYTES; QUINAZOLINES; STRUCTURE-ACTIVITY RELATIONSHIP; THIONES;

EID: 19944431381     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2004.11.015     Document Type: Article

References (17)

1. R.C. Jackson, and G. Weber Nature 256 1975 331
2. F.R. Collart, and E. Huberman J. Biol. Chem. 263 1988 15769
3. Y. Natsumeda, S. Ohno, H. Kawasaki, Y. Kanno, G. Weber, and K. Suzuki J. Biol. Chem. 265 1990 5292
4. H.N. Jayaram, M. Grusch, D.A. Cooney, and G. Krupitza Curr. Med. Chem. 6 1999 561
5. T.G.M. Dhar, Z. Shen, H.H. Gu, P. Chen, D. Norris, S.H. Watterson, S.K. Ballentine, C.A. Fleener, K.A. Rouleau, J.C. Barrish, R. Townsend, D.L. Hollenbaugh, and E.J. Iwanowicz Bioorg. Med. Chem. Lett. 13 2003 3557 and references cited therein
6. W.K. Anderson, T.L. Boehm, G.M. Makara, and R.T. Swann J. Med. Chem. 39 1996 46
7. P.H. Nelson, E. Eugui, J.C. Wu, and Y. Natsumeda J. Biol. Chem. 39 1996 46
8. T.M. Sievers, S.J. Rossi, R.M. Ghobrial, E. Arriola, P. Nishimura, M. Kawano, and C.D. Holt Pharmacotherapy 17 1997 1178
9. G. Tossing Idrugs 6 4 2003 372
10. J. Jain, S.J. Almquist, A.D. Heiser, D. Shlyakhter, E. Leon, C. Memmott, C.S. Moody, E. Nimmesgern, and C. Decker J. Pharm. Exper. Ther. 302 2002 1272
11. T.G.M. Dhar, Z. Shen, J. Guo, C. Liu, S.H. Watterson, H.H. Gu, W.J. Pitts, C.A. Fleener, K.A. Rouleau, N.Z. Sherbina, K.W. McIntyre, M.R. Witmer, J.A. Tredup, B.-C. Chen, R. Zhao, M.S. Bednarz, D.L. Cheney, J.F. MacMaster, L.M. Miller, K.K. Berry, T.W. Harper, J.C. Barrish, D.L. Hollenbaugh, and E.J. Iwanowicz J. Med. Chem. 45 2002 2127
12. M.D. Sintchak, and E. Nimmesgern Immunopharmacology 47 2000 163
13. M.D. Sintchak, M.A. Fleming, O. Futer, S.A. Raybuck, S.P. Chamber, P.R. Caron, M.A. Murcko, and K.P. Wilson Cell 85 1996 921 930
14. G. Jones, P. Willett, and R.C. Glen J. Mol. Biol. 245 1995 43 53
15. 3H thymidine is added per well and the plates incubated for a further 18 h. The final assay volume is 150 μL. The contents of the plate are then transferred to a filter plate and the cells washed with saline using the Millipore microtitre plate filtration system. The plates are dried and 100 μL of microscintillation '0' fluid is added to each well and the plate counted in the TopCount
16. 50 values, test compounds were prepared at an initial concentration of 1.0 mM in 100% DMSO, then diluted in assay buffer to 0.2 mM. Further dilutions were made in assay buffer containing 20% DMSO, prior to diluting 20-fold into the assay, to allow testing across the range 1 nM to 10 μM
17. B.A. Dressman, L.A. Spangle, and S.W. Kaldor Tetrahedron Lett. 37 7 1996 937